It has been well-characterized that the renin-angiotensin system (RAS) physiologically regulates systemic arterial pressure. However, RAS signaling has also been shown to increase cell proliferation during malignancy, and angiotensin receptor blockers (ARBs) are able to decrease pro-survival signaling by inhibiting anti-apoptotic molecules and suppressing caspase activity. In this study, the apoptotic effects of telmisartan, a type of ARB, was evaluated using a non-cancerous human renal cell line (HEK) and a human renal cell carcinoma (RCC) cell line (786). Both types of cells were treated with telmisartan for 4 h, 24 h, and 48 h, and then were assayed for levels of apoptosis, caspase-3, and Bcl-2 using MTT assays, flow cytometry, and immunostaining studies. Analysis of variance was used to identify significant differences between these data (P < 0.05). Following the treatment of 786 cells with 100 mM and 200 mM telmisartan, a marked inhibition of cell proliferation was observed. 50 mM cisplatin also caused high inhibition of these cells. Moreover, these inhibitions were both concentration-and time-dependent (P < 0.05). Various apoptotic effects were also observed compared with control cells at the 24 h and 48 h timepoints assayed (P < 0.001). Furthermore, positive caspase-3 staining and down-regulation of Bcl-2 were detected, consistent with induction of cell death. In contrast, treatment of HEK cells with telmisartan did not produce an apoptotic effect compared with control cells at the 24 h timepoint (P > 0.05). Treatment with cisplatin promoted in HEK cells high index of apoptosis (P < 0.001). Taken together, these results suggest that telmisartan induces apoptosis via down-regulation of Bcl-2 and involvement of caspase-3 in human RCC cells.
Introduction
Renal cell carcinoma (RCC) is the most common pathological pattern for 3% of the malignant tumors detected in adults. Its worldwide incidence also continues to steadily increase each year, 1 and the 5-year survival rate for pT1 and pT2 stage RCC currently ranges from 80% to 90%. However, for patients with metastatic disease, this rate is only 10%. 2, 3 Therefore, the ability to reduce risk factors associated with RCC, and the ability to identify novel therapeutics that target RCC, are extremely important. 4 Angiotensin II (Ang II) is a multifunctional, bioactive octapeptide of the renin-angiotensin system (RAS) that serves as a vasoconstrictor to control cardiovascular function and renal homeostasis. Ang II binds two subtypes of receptors to mediate its biological effects, the Ang II type 1 receptor (AT1R) and the Ang II type 2 receptor (AT2R). The former mediates the major functions of Ang II in tumor growth and angiogenesis. 5, 6 In addition, stimulation of AT1R has been shown to activate anti-apoptotic molecules such as survivin and Bcl-XL, 7 and to inactivate pro-apoptotic proteins. 8 Activation of AT1R in malignant cells can also enhance pro-survival signaling by activating: (1) nuclear factor-kB (NF-kB) and the production of anti-apoptotic molecules such as Bcl-2 and survivin, and (2) the PI3K-Akt pathway which leads to the suppression of caspases. 8 Conversely, signaling through the AT2R has been associated with the promotion of apoptosis. For example, in prostate cancer cells, overexpression of AT2R was found to induce apoptosis independent of Ang II. However, this pathway was dependent on p38 mitogen-activated protein kinase (MAPK), caspase 8, and caspase 3, and was mediated via an extrinsic cell death-signaling pathway that was partially dependent on TP53 rather than P21 activation. 9 Correspondingly, AT2R overexpression in a human lung adenocarcinoma cell line was found to reduce cell viability and to induce apoptosis, which was associated with a significant reduction in procaspase-3 levels. Thus, a disruption in the stoichiometry of AT1R and AT2R, and/or alterations in their signaling pathways, can potentially influence whether cancer cells undergo apoptosis or survive in response to activation of the RAS. 9 It is also possible that angiotensin receptor blockers (ARBs) modulate the development and progression of cancer. 10 ARBs selectively block the activation of AT1Rs, thereby suppressing the RAS. Ang II has also been characterized as an anti-apoptotic agent and growth factor, which stimulates cell replication through the epidermal growth factor receptor (EGFR) transactivation/extracellular signal-regulated kinase (ERK) signaling pathway. 11 In the present study, the objective was to evaluate the inhibitory effect of telmisartan on human renal cell carcinoma (RCC) cells and to determine whether telmisartan induces apoptosis.
Materials and methods

Reagents
The following reagents were purchased as indicated: Dulbecco's modified Eagle's medium (Life Technologies, Grand Island, NY, USA), 10% (v/v) heat-inactivated fetal bovine serum (CULTILAB LTDA/Brazil), trypsin/ EDTA (Gibco BRL, Life Technologies, Grand Island, NY, USA), cisplatin (citoplax, 50 mg, BergamoTaboão da Serra, SP, Brazil), and telmisartan (Micardis, 80 mg, BoehringerIngelheim, SP, Brazil).
Cell culture
A human non-cancerous renal cell line (HEK) and a human RCC cell line (786) were purchased from the Culture Collection of the Federal University of Rio de Janeiro (RJCB Collection, Rio de Janeiro, RJ). HEK cells were maintained in Dulbecco's modified Eagle's medium and 786 cells were maintained in RPMI 1640 medium, both supplemented with 10% (v/v) heat-inactivated fetal bovine serum. Telmisartan and cisplatin solutions were filtered using a 0.22 mm minipore membrane, then were aliquoted and stored at -20 C.
Cell proliferation studies
Approximately 1.0 Â 10 4 cells were plated on 8 Â 8 mm 2 multichamber slides (Nunc, Copenhagen, Denmark) and were treated with telmisartan (0-400 mM) and cisplatin (0-100 mM). Cell viability was subsequently measured at various timepoints using a modified 3-(4,5-dimethylthiazol-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay (WST-1 assay; Dojindo, Kumamoto, Japan) and a microplate reader. The results are presented as a percentage of the proliferation detected for control cells.
Annexin V and propidium iodide staining
Cells were plated in 6-well plates (5 Â 10 4 cells/well) with 2 mL medium/well. After 24 h, concentrations of telmisartan (100 microMolar and 200 microMolar) and cisplatin (50 microMolar) were added for 4 h, 24 h, and 48 h. In parallel, control cells were maintained in culture medium without telmisartan and cisplatin. The cells were then assayed using the Annexin V-FITC Apoptosis Detection kit I (Biosciences Pharmingen, San Diego, USA). Annexin V-FITC and propidium iodide (PI) were added to the cellular suspension according to the manufacturer's instructions. A total of 1.0 Â 10 6 cells from each sample were then analyzed using a FACSCalibur cytometer (BD Bioscience, Franklin Lakes, NJ, USA) and FlowJo software (BD Biosciences). Annexin V-FITC-positive/PI-negative cells were identified as cells in the early stages of apoptosis, while Annexin V-FITC-positive/PI-positive cells were identified as cells in the late stages of apoptosis, or cells that were undergoing necrosis.
Caspase-3 and Bcl-2 activities
After 24 h, the cells (5 Â 10 4 cells/well) were treated with telmisartan (100 mM and 200 mM) and cisplatin (50 mM) in 24-well plates. After 24 h and 48 h, cells were washed, fixed with paraformaldehyde, permeabilized with Triton-X, and incubated with rabbit polyclonal anti-caspase-3 antibody (Abcam, San Francisco, CA, USA) or rat polyclonal anti-Bcl-2 antibody (Abcam). Both antibody solutions were diluted 1:500 in PBS containing bovine serum albumin (5%; Life Technologies do Brasil LTDA, São Paulo, Brazil). After an incubation at RT in a humid atmosphere for 1 h, the coverslips were incubated with AlexaFluor 488 anti-rabbit or anti-rat secondary antibody (Abcam). In addition, nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI, Life Technologies do Brasil LTDA). Slides were subsequently examined using a binocular optical microscope (Nikon Eclipse 80i, Tokyo, Japan) using a 60 Â oil objective, and imaged using Neurolucida software (MBF Bioscience, Williston, VT, USA).
Statistical analysis
All experiments were performed at least in triplicate. Significant differences between groups were calculated by applying analysis of variance and Bonferroni's test, as indicated. A P value less than 0.05 was considered statistically significant.
Results
Telmisartan inhibits the growth of 786 RCC cells
To investigate the effects of telmisartan on RCC cell proliferation, a modified MTT assay was used to analyze cell viability in vitro. Following the treatment of RCC cell lines with telmisartan reduced cell viability was observed. Moreover, the half-maximal concentration that inhibited the growth of RCC cells ranged from 100 to 400 mM ( Figure 1 ). When cells were counted 24 h after the addition of telmisartan, a marked inhibition of cell proliferation was especially observed for concentrations of 100 mM and 200 mM telmisartan ( Figure 1 ).
When cells were treated with cisplatin, a reduction in cell viability was also observed, with the half-maximal concentration to achieve growth inhibition ranging from 25 to 100 mL ( Figure 2 ). Moreover, although cisplatin was found to inhibit the growth of RCC cells at all of the concentrations tested, a marked inhibition of cell proliferation was observed at a concentration of 50 mM cisplatin at the 24 h timepoint ( Figure 2 ).
Induction of apoptosis by telmisartan was evaluated using flow cytometry
To determine whether cell death induced by telmisartan was achieved through apoptosis, cells were treated with telmisartan and stained with Annexin-V-FITC and PI. Using flow cytometry, early and late stages of apoptosis were detected based on the percentage of Annexin V-FITC-positive cells/PI-negative cells and the percentage of Annexin V-FITC-positive/PI-positive cells that were present, respectively ( 
Caspase-3 and Bcl-2 activities
To study the mechanism(s) that mediate telmisartaninduced apoptosis, activation of caspase-3 and Bcl-2 activities were examined in telmisartan-treated cells using immunofluorescence microscopy. In Figure 5 , representative images of 786 RCC cells and normal HEK cells treated with telmisartan and cisplatin treatment are shown. The absence of caspase-3 staining indicates that the death of HEK cells 24 h after treatment with telmisartan is not mediated by an apoptotic process ( Figure 5(j) ). Conversely, positive staining for caspase-3 that was observed for 786 cells following treatment with telmisartan indicates that the cell death induced is mediated by an apoptotic process ( Figure 5(b) and (c)). Positive staining for caspase-3 with DAPI staining is also shown ( Figure 5 (b.1) and (b.2)).
Negative staining for Bcl-2 was observed for 786 cells following treatment with telmisartan, and these results indicate that this treatment blocked the activity of Bcl-2 ( Figure 5(f) and (g) ). Furthermore, treatment of 786 cells with 50 mM cisplatin resulted in apoptosis that was accompanied by caspase-3 activation ( Figure 5(d) ) and downregulation of Bcl-2 ( Figure 5(h) ). Similar results were obtained for HEK cells treated with cisplatin ( Figure 5(k) ).
Discussion
Internal stimuli, such as irreparable genetic damage, hypoxia, extremely high concentrations of cytosolic Ca 2þ , and severe oxidative stress, can trigger the intrinsic mitochondrial pathway of apoptosis. 12 Moreover, regardless of stimuli, this pathway leads to increased mitochondrial permeability and the release of pro-apoptotic molecules, such as cytochrome c, into the cytoplasm. 12 This pathway is closely regulated by a group of proteins belonging to the Bcl-2 family, 13 which includes pro-apoptotic proteins (e.g. Bax, Bak, Bad, Bcl-Xs, Bid, Bik, Bim, and Hrk) and antiapoptotic proteins (e.g. Bcl-2, Bcl-XL, Bcl-W, Bfl-1, and Mcl-1). 14 While the latter regulate apoptosis by blocking the mitochondrial release of cytochrome c, the former promote the release of cytochrome c. 15 Anti-apoptotic proteins have also been found to be up-regulated in a variety of tumor types. 16 Both the release of cytochrome c into the cytoplasm during the early stages of apoptosis, prior to caspase activation, DNA fragmentation, and loss of membrane potential, 9 and the blockade of anti-apoptotic Bcl-2 proteins integrated into the outer mitochondrial membrane, are mediated during the early stages of apoptosis. 10 The execution phase of apoptosis involves the activation of a series of caspases. The upstream caspase for the intrinsic pathway is caspase 9, which can activate caspase-3. Caspase-3 then cleaves the inhibitor of the caspase-activated deoxyribonuclease which is responsible for nuclear apoptosis. 17, 18 Downstream caspases induce cleavage of protein kinases, cytoskeletal proteins, DNA repair proteins, and inhibitory subunits of endonuclease families. Correspondingly, they affect the cytoskeleton, cell cycle progression, and various signaling pathways, thereby mediating the morphological changes that accompany apoptosis. 18 Events involving caspase activation and DNA fragmentation are also related to the late stages of apoptosis. 19 In the present study, the pro-apoptotic activity of telmisartan was investigated using 786 RCC cells. It was observed that telmisartan significantly inhibited the growth of this cell line in a dose-dependent manner (Figure 1) . Moreover, both 100 mM and 200 mM concentrations of telmisartan induced either early-or late-stage apoptosis within 24 h or 48 h of treatment (Figure 3) . These results are consistent with previous studies. 20 Telmisartan has also been shown to mediate potent early apoptotic effects against prostate cancer cells and urological cancer cells. 21, 22 In the present study, while treatment with 100 mM telmisartan did not induce apoptosis in normal HEK cells up to 24 h after treatment, a distinct increase in late stage apoptosis was observed by the 48 h timepoint. These results were further confirmed by an absence of caspase-3 labeling at the 24 h timepoint ( Figure 5(i) ), and were also consistent with previous results. 22 Apoptosis was observed when levels of Bcl-2 family proteins decreased and caspase-3 was activated, both of which are well-characterized regulators of apoptosis. Accordingly, high levels of caspase-3 expression were detected in 786 RCC cells in the present study ( Figure 5(b) and (c)), which corresponded with the late stages of apoptosis that were detected following treatment with telmisartan. Apoptotic activity has also been detected following the treatment of cells with other ARBs, and this was accompanied by increased expression of caspase-3. 23 In particular, blockage of AT1R has been found to stimulate apoptosis in cancer cells. 24 Furthermore, in a transgenic rat model of adenocarcinoma of prostate (TRAP), telmisartan and candesartan were found to attenuate prostate carcinogenesis by enhancing the apoptosis induced by the activation of various caspases. 25 In the present study, expression of Bcl-2 in 786 RCC cells treated with 100 mM or 200 mM telmisartan decreased within 24 h, indicating that telmisartan induces early apoptosis by down-regulating the expression of Bcl-2 genes. Similarly, losartan, another type of ARB, was found to mediate a dose-dependent decrease in cell survival, an increase in levels of p53, p21, p27, and Bax, and a reduction in Bcl-2 and Bcl-xl levels in human pancreatic cells. 26 Ang II is a vasoconstrictor that controls cardiovascular function and renal homeostasis. Recently, it has been shown that Ang II stimulates tumor growth and angiogenesis, especially in chorio-carcinomas, 27 breast cancer, 28 ovarian cancer, 29 and pancreatic cancer. 7 Taken together, these observations suggest that Ang II may have a role in cancer development. It has been shown that the major functions of Ang II in tumor growth and angiogenesis are mediated through AT1R. 5, 6 Moreover, it was recently demonstrated that stimulation of AT1R can trigger the activation of phosphatidylinositol 3 (PI3)-kinase and Akt, 30 with the latter phosphorylating pro-apoptotic proteins including Bad, caspase-9, and forkhead transcription factors [31] [32] [33] to inhibit apoptosis. Ang II has also been reported to significantly prevent cisplatininduced apoptosis via activation of NF-kB and the subsequent production of anti-apoptotic molecules. 34 In the present study, a greater number of cells treated with cisplatin were detected in the later stage of apoptosis than in the early stage of apoptosis in both cancer and normal cells (P < 0.001).
Drugs or treatment strategies that restore the normal function of apoptotic signaling pathways have the potential to eliminate cancer cells which otherwise depend on these defects for survival. While research is ongoing to identify new classes of anticancer drugs, ARBs are considered a significant anticancer, anti-angiogenesis, and anti-inflammatory therapeutic option. [35] [36] [37] In conclusion, treatment of 786 RCC cells resulted in a significant increase in the number of cells undergoing apoptosis. Furthermore, this apoptosis was accompanied by down-regulation of Bcl-2 and activation of caspase-3dependent signaling. Based on these results, telmisartan appears to represent a potential therapeutic candidate for the treatment of cancer.
